Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2473–2496 of 9,549 matching trials from the live ClinicalTrials.gov search.

Filters: Birmingham, Alabama Clear all

Conditions: Primary Mediastinal Large B-Cell Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide Phosphate, Filgrastim, Lumbar Puncture, Nivolumab, Pegfilgrastim, Positron Emission Tomography, Prednisolone, Prednisone, Radiation Therapy, Rituximab, Rituximab and Hyaluronidase Human, Vincristine Sulfate; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 215
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 162 more

Conditions: Brain and Central Nervous System Tumors
Interventions: suramin, radiation therapy; Drug · Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 9
States / cities: Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more

Conditions: Schizophrenia
Interventions: quetiapine fumarate vs risperidone; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 64
States / cities: Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 61 more

Conditions: Systemic Lupus Erythematosus
Interventions: CEP-33457; Drug
Lead sponsor: Cephalon, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 39
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 33 more

Conditions: Endometrial Cancer
Interventions: alvocidib; Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 50
States / cities: Birmingham, Alabama • Los Angeles, California • Los Gatos, California + 42 more

Conditions: Heart Failure
Interventions: Omecamtiv Mecarbil, Placebo, Standard of Care; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 8,256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 310
States / cities: Birmingham, Alabama • Fort Payne, Alabama • Huntsville, Alabama + 249 more

Conditions: Spinal Cord Injury
Interventions: CSFD and elevation of MAP, Maintenance of MAP; Procedure
Lead sponsor: St. Joseph's Hospital and Medical Center, Phoenix; Other
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 3
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona

Conditions: Type 2 Diabetes
Interventions: Not listed
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 4,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 165
States / cities: Birmingham, Alabama • Columbiana, Alabama • Mobile, Alabama + 162 more

Conditions: Contraception
Interventions: Norgestrel 0.075 mg tablets; Drug
Lead sponsor: HRA Pharma; Industry
Eligibility: 11 Years and older · Female only
Enrollment: 962 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 38
States / cities: Birmingham, Alabama • Homewood, Alabama • Mesa, Arizona + 29 more

Conditions: Type 2 Diabetes Mellitus, Cardiovascular Disease, Inadequate Glycaemic Control
Interventions: Dapagliflozin, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 45 Years and older
Enrollment: 964 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 57
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Anaheim, California + 54 more

Conditions: Type 2 Diabetes
Interventions: ITCA 650, ITCA placebo; Drug · Other
Lead sponsor: Intarcia Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 121
States / cities: Birmingham, Alabama • Gulf Shores, Alabama • Huntsville, Alabama + 102 more

Conditions: Invasive Fungal Infections
Interventions: SUBA itraconazole, Conventional itraconazole; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 11
States / cities: Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 7 more

Conditions: Chronic Hepatitis C Virus
Interventions: VX-222, telaprevir, ribavirin; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 18
States / cities: Birmingham, Alabama • Anaheim, California • Riverside, California + 15 more

Conditions: Bacterial Vaginosis
Interventions: Metronidazole; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 15 Years to 25 Years · Female only
Enrollment: 1,370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 7
States / cities: Birmingham, Alabama • San Francisco, California • Baltimore, Maryland + 3 more

Conditions: Brain Metastases
Interventions: Stereotactic Radiosurgery (15 Gy), Stereotactic Radiosurgery (12 Gy); Radiation
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Pain, Postoperative
Interventions: Sufentanil NanoTab PCA System/15 mcg; Drug
Lead sponsor: Talphera, Inc; Industry
Eligibility: 45 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 3
States / cities: Birmingham, Alabama • Vero Beach, Florida • Houston, Texas

Conditions: Burns, Wound Heal
Interventions: DeepView SnapShot Portable (DV-SSP); Device
Lead sponsor: SpectralMD; Industry
Eligibility: Not listed
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 11
States / cities: Birmingham, Alabama • Phoenix, Arizona • Bridgeport, Connecticut + 7 more

Conditions: COVID-19
Interventions: ADG20, Placebo; Drug
Lead sponsor: Invivyd, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 2,582 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 66
States / cities: Birmingham, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 60 more

Conditions: Systemic Lupus Erythematosus
Interventions: SAR441344 IV, SAR441344 SC, Placebo IV, Placebo SC; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 22
States / cities: Vestavia Hills, Alabama • Chandler, Arizona • Mesa, Arizona + 19 more

Conditions: Huntington's Disease
Interventions: Creatine Monohydrate, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 553 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 38
States / cities: Birmingham, Alabama • Irvine, California • Sacramento, California + 35 more

Conditions: Embryonal Rhabdomyosarcoma, Fusion-Negative Alveolar Rhabdomyosarcoma, Spindle Cell/Sclerosing Rhabdomyosarcoma
Interventions: Biopsy Procedure, Bone Scan, Computed Tomography, Cyclophosphamide, Dactinomycin, Magnetic Resonance Elastography, Positron Emission Tomography, Radiation Therapy, Vincristine; Procedure · Drug · Biological + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 166
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 129 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Lamivudine/Zidovudine, Ritonavir, Amprenavir, Efavirenz, Saquinavir, Lamivudine, Stavudine, Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 38
States / cities: Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 23 more

Conditions: Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions: Autologous cultured dermal and epidermal cells; Biological
Lead sponsor: Aderans Research Institute; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2010
U.S. locations: 4
States / cities: Birmingham, Alabama • Tucson, Arizona • Pinellas Park, Florida + 1 more

Conditions: Moderate to Severe Glabellar Lines
Interventions: Corabotase, Placebo; Biological
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 17
States / cities: Birmingham, Alabama • Glendale, Arizona • Scottsdale, Arizona + 13 more

Search by objective public record fields.

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Suramin Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

A Comparison of Seroquel vs. Risperidone in Schizophrenia

A Long-Term Study of the Safety and Tolerability of Repeated Administration of CEP-33457 in Participants With Systemic Lupus Erythematosus

Flavopiridol in Treating Patients With Recurrent or Persistent Endometrial Cancer

Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction

Cerebrospinal Fluid Drainage (CSFD) in Acute Spinal Cord Injury

G-PLUS (GALLANT, GALLEX and ARMOR - Post Treatment Follow-up Study)

Adherence With Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and Use

Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease

A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes

Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole

VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C

Bacterial Vaginosis Home Screening to Prevent STDs

Dose Escalation/De-escalation Study of Pre-operative Stereotactic Radiosurgery for Brain Metastases(RAD 1002)

An Open-Label Functionality, Safety and Efficacy Study in Patients Undergoing Elective Unilateral Knee Replacement

DeepView SnapShot Portable (DV-SSP): Device Training Study

Evaluation of ADG20 for the Prevention of COVID-19

Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus

Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure

A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004541)

A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows